{
  "source": "PA-Notification-Rydapt.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1220-9\nProgram Prior Authorization/Notification\nMedication Rydapt® (midostaurin)\nP&T Approval Date 6/2017, 6/2018, 6/2019, 6/2020, 6/2021, 6/2022, 6/2023, 6/2024. 6/2025\nEffective Date 9/1/2025\n1. Background:\nRydapt® (midostaurin) is a kinase inhibitor indicated for the treatment of adult patients with\nnewly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, in combination\nwith standard cytarabine and daunorubicin induction and cytarabine consolidation. Rydapt is not\nindicated as a single-agent induction therapy for the treatment of patients with AML.\nRydapt is also indicated for aggressive systemic mastocytosis (ASM), systemic mastocytosis with\nassociated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).\nThe National Comprehensive Cancer Network (NCCN) also recommends Rydapt for treatment of\nmyeloid/lymphoid neoplasms with eosinophilia and FGFR1 or FLT3 rearrangements.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Rydapt will be approved based on the following criterion:\na. Member is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Acute Myeloid Leukemia (AML)\n1. Initial Authorization\na. Rydapt will be approved based on all of the following criteria:\n(1) Diagnosis of acute myeloid leukemia (AML)\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\n(2) AML is FLT3 mutation-positive\n-AND-\n(3) Rydapt will be used in combination with standard induction",
    "eria:\n(1) Diagnosis of acute myeloid leukemia (AML)\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\n(2) AML is FLT3 mutation-positive\n-AND-\n(3) Rydapt will be used in combination with standard induction and consolidation\ntherapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rydapt will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Rydapt therapy\nAuthorization will be issued for 12 months.\nC. Systemic Mastocytosis\n1. Initial Authorization\na. Rydapt will be approved based on the following criterion:\n(1) Diagnosis of one of the following:\n(a) Aggressive systemic mastocytosis (ASM)\n(b) Systemic mastocytosis with associated hematologic neoplasm (SM-AHN)\n(c) Mast cell leukemia (MCL)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rydapt will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Rydapt therapy\nAuthorization will be issued for 12 months.\nD. Myeloid/Lymphoid Neoplasms\n1. Initial Authorization\na. Rydapt will be approved based on both of the following criteria:\n(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n2\n(2) One of the following:\n(a) Presence of an FGFR1 rearrangement\n(b) Presence of an FLT3 rearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rydapt will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Rydapt therapy.\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage cr",
    "dium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Rydapt [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; May 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed April 30. 2025.\nProgram Prior Authorization/Notification - Rydapt (midostaurin)\nChange Control\n6/2017 New program.\n6/2018 Annual review with no changes to criteria. Updated reference.\n6/2019 Annual review with no changes to criteria. Updated reference.\n6/2020 Annual review with no changes to criteria. Updated reference.\n6/2021 Annual review. Added myeloid/lymphoid neoplasms criteria per NCCN\nguideline update. Updated references.\n6/2022 Annual review. Revised grammar in criteria with no changes to clinical\nintent. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n3\n6/2023 Annual review with no changes to clinical criteria. Updated references\nand added state mandate footnote.\n6/2024 Annual review with no changes to clinical criteria. Updated references.\n6/2025 Annual review. Revised wording in criteria for myeloid/lymphoid\nneoplasms with no changes to clinical intent. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n4"
  ]
}